ServicenavigationHauptnavigationTrailKarteikarten


Research unit
INNOSUISSE
Project number
59256.1 IP-LS
Project title
Defining the pharmacology, safety, and dosing of #PB-FC# a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease

Participants

Research organisation: Innosuisse
Swiss Innovation Agency
Einsteinstrasse 2
CH-3003 Bern
+41 58 461 61 61 (Call Center)
info@innosuisse.ch
www.innosuisse.ch/
Contact person

Markus Arnoldini
ETH Zürich
Vladimir-Prelog-Weg 3
CH-8093 Zürich


Implementation Partner

Gabriel Leventhal
PharmaBiome AG
CHE-190.589.234
Wagistrasse 27
CH-8952 Schlieren